Kalvista Pharmaceuticals (NASDAQ:KALV) had its price objective raised by Roth Capital from $25.00 to $30.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.
A number of other analysts have also recently issued reports on the company. BidaskClub upgraded Kalvista Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday. Needham & Company LLC began coverage on Kalvista Pharmaceuticals in a report on Wednesday, March 20th. They issued a buy rating and a $35.00 price target for the company. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a hold rating to a strong-buy rating and set a $26.00 price target for the company in a report on Saturday, March 2nd. Finally, ValuEngine upgraded Kalvista Pharmaceuticals from a hold rating to a buy rating in a report on Monday, February 4th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Kalvista Pharmaceuticals presently has an average rating of Buy and a consensus price target of $30.60.
Shares of NASDAQ:KALV traded up $0.42 during trading on Wednesday, reaching $24.65. 2,925 shares of the stock were exchanged, compared to its average volume of 121,332. Kalvista Pharmaceuticals has a 12-month low of $7.73 and a 12-month high of $34.92. The stock has a market capitalization of $420.48 million, a P/E ratio of -15.80 and a beta of 2.32.
Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative return on equity of 19.12% and a negative net margin of 70.08%. The business had revenue of $3.89 million during the quarter, compared to analysts’ expectations of $3.97 million. Research analysts expect that Kalvista Pharmaceuticals will post -1.43 EPS for the current year.
In other Kalvista Pharmaceuticals news, major shareholder Svlsf Iv, Llc sold 43,378 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $22.91, for a total value of $993,789.98. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Benjamin L. Palleiko sold 3,073 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $25.70, for a total value of $78,976.10. Following the completion of the transaction, the chief financial officer now directly owns 33,573 shares in the company, valued at $862,826.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,115,719 shares of company stock valued at $29,999,337. 38.40% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Flinton Capital Management LLC acquired a new position in shares of Kalvista Pharmaceuticals in the 4th quarter valued at approximately $26,000. Ramsey Quantitative Systems acquired a new position in shares of Kalvista Pharmaceuticals in the 4th quarter valued at approximately $35,000. Bank of Montreal Can acquired a new position in shares of Kalvista Pharmaceuticals in the 4th quarter valued at approximately $90,000. Marshall Wace North America L.P. acquired a new position in shares of Kalvista Pharmaceuticals in the 1st quarter valued at approximately $175,000. Finally, Morgan Stanley raised its position in shares of Kalvista Pharmaceuticals by 780.7% in the 1st quarter. Morgan Stanley now owns 7,486 shares of the specialty pharmaceutical company’s stock valued at $214,000 after purchasing an additional 6,636 shares in the last quarter. 77.44% of the stock is currently owned by institutional investors.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Further Reading: P/E Growth (PEG)
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.